Novo Nordisk A/S is spending 15.9 billion Danish kroner ($2.29 billion) to expand production facilities in Denmark as the obesity drug manufacturer looks to ensure capacity for its future portfolio.

The investment in Hillerød, Denmark is planned to create additional production for its pipeline drugs to fight serious chronic diseases, Novo said in a statement Monday. The expansion is unrelated to semaglutide, the active ingredient in its obesity and diabetes medicines Wegovy and Ozempic, Novo said.